Enzolytics, Inc.

Equities

ENZC

US2941121079

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:50:00 2024-05-31 EDT			5-day change	1st Jan Change
0.0037 ^USD	+7.25%		+5.71%	-78.86%

05-02	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
03-25	Enzolytics, Inc. Announces Board Changes	CI

Structural Enhancement Technologies Corp cancelled the acquisition of bottling facility in Bedford Park, Illinois.

June 22, 2013 at 12:00 am

Structural Enhancement Technologies Corp (OTCPK:EMWW) entered into an agreement to acquire a bottling facility in Bedford Park, Illinois on June 22, 2012.

Structural Enhancement Technologies Corp (OTCPK:EMWW) cancelled the acquisition of bottling facility in Bedford Park, Illinois on June 22, 2013.

Latest news about Enzolytics, Inc.

Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	05-02	CI
Enzolytics, Inc. Announces Board Changes	03-25	CI
Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	03-25	CI
Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	03-25	CI
Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	23-06-26	CI
Enzolytics, Inc. Provides Update on Clinical Trials	23-04-21	CI
Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	23-04-16	CI
Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	23-02-08	CI
Enzolytics to Develop Feline Monoclonal Antibodies	23-01-03	CI
Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	22-12-13	CI
Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	22-11-16	CI
Enzolytics, Inc. Appoints Dr. Kirsten Bischof to Its Advisory Board	22-10-24	CI
Enzolytics Inc. Reports Successful Completion of an MTD Tolerability Study of Its ITV-1 anti-HIV Therapeutic Leading to the Start of a 28-day GLP Toxicology Study	22-10-05	CI
Enzolytics Inc. Announces Collaboration with Abveris to Discover Monoclonal Antibodies	22-09-16	CI
Enzolytics Inc. and Samsung Biologics Co., Ltd. Announce Development and Manufacturing Agreement	21-10-07	CI
Enzolytics Inc. completed the acquisition of BioClonetics Immunotherapeutics, Inc.	20-11-30	CI
Enzolytics, Inc. Announces Appointment of Ronald Moss to the Medical Advisory Board	20-11-10	CI
Enzolytics Inc. announced that it has received $0.25 million in funding	20-11-09	CI
Enzolytics Inc. Announces the Appointment of Charles Cotropia as CEO	20-10-22	CI
Enzolytics Inc. Appoints Harry Zhabilov as CSO	20-10-22	CI
Enzolytics Inc. executed a non-binding letter of intent to acquire BioClonetics Immunotherapeutics, Inc.	20-09-15	CI
Eco-Petroleum Solutions, Inc. will Change its Name to Enzolytics Inc	18-03-22	CI
Enzolytics Inc. will Change its Ticker to ENZC from ECPO	18-03-22	CI
Eco Petroleum Solutions, Inc. Announces Exclusive Distribution Agreement with IMMB BG	17-06-22	CI
Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	17-06-13	CI

Chart Enzolytics, Inc.

Duration

Period

More charts

Company Profile

Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENZOLYTICS, INC.	-78.86%	12.33M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs